NCT06145633View on ClinicalTrials.gov

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2027

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT, PET/CT, SPECT/CT

OTHER

Fludeoxyglucose F-18

Undergo FDG PET/CT

OTHER

Gallium Ga 68 Gozetotide

Given IV

DRUG

Lutetium Lu 177 Vipivotide Tetraxetan

Given 177Lu-PSMA-617

PROCEDURE

Positron Emission Tomography

Undergo 68Ga-PSMA-11 PET

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT/CT

DRUG

Vorinostat

Given IV

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Institute for Prostate Cancer Research (IPCR)

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER